MARKET

CGEN

CGEN

Compugen
NASDAQ
0.9763
+0.0163
+1.70%
Pre Market: 0.9500 -0.0263 -2.69% 09:03 11/28 EST
OPEN
0.9527
PREV CLOSE
0.9600
HIGH
1.040
LOW
0.8601
VOLUME
3.47K
TURNOVER
--
52 WEEK HIGH
4.880
52 WEEK LOW
0.5100
MARKET CAP
84.57M
P/E (TTM)
-2.1462
1D
5D
1M
3M
1Y
5Y
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Benzinga · 11/18 10:14
Compugen to get $7.5M milestone as AstraZeneca begins dosing in cancer drug study
Seekingalpha · 11/16 13:31
BRIEF-Compugen To Receive Milestone Payment Triggered By Astrazeneca's Phase 2 Initiation Of Pd-1/Tigit Bispecific
Reuters · 11/16 12:11
Oppenheimer Maintains Outperform on Compugen, Lowers Price Target to $8
Benzinga · 11/15 11:36
--Oppenheimer Adjusts Compugen PT to $8 From $12, Updates Model to Reflect Evolving Development Strategy; Maintains Outperform Rating
--Oppenheimer Adjusts Compugen PT to $8 From $12, Updates Model to Reflect Evolving Development Strategy; Maintains Outperform Rating
MT Newswires · 11/15 10:39
BRIEF-Compugen Reports Third Quarter 2022 Results
Reuters · 11/14 13:02
Compugen GAAP EPS of -$0.14 misses by $0.01
Seekingalpha · 11/14 12:02
Compugen Q3 EPS $(0.14) Misses $(0.10) Estimate. Cash, Cash Equivalents, Short-Term Bank Deposits, Restricted Cash Of $88M
Benzinga · 11/14 12:01
More
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Webull offers kinds of Compugen Ltd. (USA) stock information, including NASDAQ:CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.